Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Is It Too Early to Predict the Failure of Natalizumab in NMO?
Fatigue and its association with sleep disorders, depressive symptoms and anxiety in patients with multiple sclerosis.
Peptidylarginine deiminase and protein citrullination in prion diseases: Strong evidence of neurodegeneration.
Predicting degree of myelination based on diffusion tensor imagining of canines with mucopolysaccharidosis type I.
Scutellarin Alleviates Behavioral Deficits in a Mouse Model of Multiple Sclerosis, Possibly Through Protecting Neural Stem Cells.
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.
Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway.
Functional Cognitive Disorder: A Common Cause of Subjective Cognitive Symptoms.
Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study.
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data.
[Spinal segmental myoclonus in multiple sclerosis (case report).]
Chromatic visual evoked potentials in young patients with demyelinating disease.
Expression and localization of aquaporin-4 in sensory ganglia.
Pathogenesis of Pediatric Multiple Sclerosis.
Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop.
Molecular mimicry as a mechanism for food immune reactivities and autoimmunity.
Information processing speed and attention in multiple sclerosis: Reconsidering the Attention Network Test (ANT).
[Neurodegeneration in multiple sclerosis and the neuroprotective effect of glatiramer acetate: a literature review].
Cerebrospinal fluid concentrations of ghrelin in patients with multiple sclerosis.
Subclinical Optic Neuritis in Neuromyelitis Optica.
S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.
Unemployment among women with multiple sclerosis: the role of coping and perceived stress and support in the workplace.
Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases.
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
Pages
« first
‹ previous
…
371
372
373
374
375
376
377
378
379
…
next ›
last »